Chancellor Jeremy Hunt has announced a comprehensive ‘Life Sci for Growth’ package of support for the UK life sciences sector, designed to grow the economy through improving regulation around clinical trials, manufacturing, skills and infrastructure.
The European Medicines Agency (EMA) has published its annual report for 2022, highlighting its challenges and successes in a year that saw it face ongoing and new public health emergencies.
Decentralised clinical trials (DCTs) are being used increasingly in the pharma industry for clinical research and the US Food and Drug Administration (FDA) has published draft guidance for those carrying out trials at non-traditional investigation sites.
Cancer diagnosis and treatment are set to be accelerated with the opening of England’s first Integrated Pathology Unit (IPU). The new facility will apply pioneering digital imaging and artificial intelligence to pathology, assisting clinical trial research programmes focused on developing tests for cancer.
The 2023 annual conference of the UK’s Association of the British Pharmaceutical Industry (ABPI) at the end of April had a theme of Growing the UK as a Global Hub for Life Sciences.
In order to strengthen the UK’s regulatory environment for clinical trials in an increasingly competitive global market, the government plans to prioritise safety and efficacy, while minimising regulatory burdens on trial sponsors.
The recently published ‘Advancing Clinical Trials’ report puts forward equality, diversity and inclusion (EDI) in clinical trials as central to the future of in the UK’s life sciences industry.
A free webinar on the M11 Guideline has been organised by the International Council for Harmonisation (ICH) M11 Expert Working Group (EWG). The Guideline is an initiative to promote greater harmonisation across international clinical trial protocols. The webinar takes place on 26 January 2023 at 10am-12pm EST (3-5pm GMT).
The European Medicines Agency (EMA) has issued a reminder that from 31 January 2023 clinical trial sponsors must use the Clinical Trials Information System (CTIS) for initial trial applications.
ABPI report warns UK is losing its global standing in clinical trials. The research ‘Rescuing Patient Access to Industry Clinical Trials in the UK’ shows that the number of industry clinical trials initiated in the UK per year fell by 41% between 2017 and 2021, with cancer trials falling by the same margin.
